MAY 13-14, 2023 – DUBLIN, IRELAND

The NEW HORIZONS GIST Patient Advocacy Roundtable: Improving access to treatment and quality of care through global exchange



Ne

MAY 13-14, 2023 – DUBLIN, IRELAND



PROGRAMME

Crowne Plaza Dublin Blanchardstown Blanchardstown Town Centre, Dublin, Ireland

SATURDAY May 13, 2023

14:00 (15)	Opening & Welcome NH GIST Steering Committee
14:15 - 16:00 (105)	HYBRID Session Chairs: Martin Wettstein & Piga Fernandez
	How to treat GIST (Gastrointestinal Stromal Tumors) qualified today? The previous therapy algorithms: overview and changes/innovations
	 The localized disease The metastatic disease The progressive disease Robin Jones, UK
16:00 - 16:30	COFFEE BREAK (30 mins)
16:30 - 18:15 (105)	HYBRID Session Chairs: Sara Rothschild & Ginger Sawyer
	Scientific evidence and expert evidence (= practical clinical experience) with the two latest approved GIST therapies: • Fourth line: Ripretinib (Qinlock®) • For GIST Exon D842V: Avapritinib (Ayvakit® / Ayvakyt®) Jon Trent, USA
18:15 - 19:30	BREAK BEFORE DINNER (90 mins)
19:30	Onsite: Conference Dinner (external dinner)

Alla ana

Title: The Convention Centre in the Dublin Docklands, Dublin, Ireland. © wikipedia commons J.-H. Janßen



6

MAY 13-14, 2023 – DUBLIN, IRELAND



SUNDAY May 14, 2023

10:00 - 12:30	Working Group
(150)	HYBRID
incl. break (15)	Session Chairs: David Josephy & Markus Wartenberg
	GIST patients urgently need innovations and improvements for survival and better quality of life. What are the top research questions/priorities from the patient perspective? Let's identify and prioritize unanswered questions or evidence uncertainties in GIST!
	<u>A two-step process:</u>
	Phase 1: Before the conference, we will collect research questions and priorities from the global GIST patient advocacy community.
	Phase 2: During the conference we will discuss a list of the most frequently mentioned topics with each other and with leading GIST-Experts.
	Our goal: A 10-point list with the main research questions/priorities from the perspective of GIST patients.
	(Mid-term-goal: A joint publication)
	GIST-Experts onsite and online:
	Peter Reichardt, Germany, Robin Jones, UK, Jon Trent, USA, Marco Baia, IT
12:30 - 13:30	L U N C H (60 mins)
13:30 - 15:15 (105)	HYBRID Session Chairs: Jayne Bressington & Gerard van Oortmerssen
	Right from the start, GISTs were one of the first cancer diseases for "precision oncology". That means: The right therapy for specific mutations/target structures. One challenge today are rare and very rare GIST subtypes (e.g. rare exon mutations and non-KIT/-PDGFRA GIST).
	 General overview of rare and very rare GISTs -biology, genetics and profiles of the individual subtypes PatholoGIST: Florian Haller, Germany
	• How to treat rare GIST-subtypes – scientific & expert evidence OncoloGIST: Ramesh Bulusu, UK
	 Patients and experts are working closely together in rare GIST subtypes: The UK-experience Jayne Bressington, UK
	 Patients and experts are working closely together in rare GIST subtypes: The US-experience John Glod, USA
15:15 - 15:45	COFFEE BREAK (30 mins)



MAY 13-14, 2023 – DUBLIN, IRELAND



SUNDAY May 14, 2023 continued

15:45 - 17:30	HYBRID
(105)	Chairs: David Josephy & Markus Wartenberg
	Part A:
	Where does the GIST research journey currently take us? What's happening
	 in basic research (incl. ctDNA)
	in clinical research / in clinical studies Cesar Serrano, ES
	Questions/comments from the audience and from the virtual meeting room
	Part B:
	Morning results of this conference: Findings from a survey among the global GIST patient advocacy community and from a workshop today with leading GIST-Experts:
	A 10-point list with the main research questions/priorities from the perspective of GIST patients David Josephy & Markus Wartenberg
	Questions/comments from the audience and from the virtual meeting room
17:30	Wrap Up & Farewell - OFFICIAL END OF THE CONFERENCE



Sponsors of the New Horizons GIST conference 2023



